ライフサイエンスコーパス: mph

1 dmill at 1.6, 3.2, and 4.8 km/h (1, 2, and 3 mph).

2 data is multiparameter persistent homology (MPH).

3 g memory and divided attention (MAAT/MPH>ABT/MPH).

4 ng ability (SCA) and mid-parental heterosis (MPH).

5 ose sensitivity to the beneficial actions of MPH.

6 ll strikes with a ball propelled at 30 to 40 mph.

7 fter oral administration of various doses of MPH.

8 lar collagen surrounded by F4/80-positive MC/Mph.

9 patients who are more likely to benefit from MPH.

10 of VF with a baseball propelled at 20 to 70 mph.

11 olunteers were studied with SPECT on and off MPH.

12 tial mechanisms of the therapeutic action of MPH.

13 double-blinded, placebo-controlled trial of MPH.

14 ized in apposition to infiltrating CD11b+ Mo/Mph.

15 iC3b can modulate the cytokine profile of Mo/Mph.

16 chieved when vehicle speed sustained over 45 mph.

17 ence+placebo and (c) 24 h smoking abstinence+MPH.

18 Treatment with MPH (0.125 mg/kg), ATMX (0.125 mg/kg), or EX (3 weeks of

19 es, the effects of varying concentrations of MPH (0.25, 1.0, and 4.0 muM) on NE and DA efflux were ex

20 cross-over trial of placebo (bid), low-dose MPH (0.3 mg/kg; maximum dose, 10 mg bid), and moderate-d

21 disorder (CUD) twice after placebo and after MPH (0.5 mg/kg, iv).

22 The patients ingested a placebo (lactose) or MPH (0.6 mg/kg; 20 mg maximum) and repeated selected por

23 maximum dose, 10 mg bid), and moderate-dose MPH (0.6 mg/kg; maximum dose, 20 mg bid).

24 microinfusion of vehicle or varying doses of MPH (.03-8.0 mug/500 nL) directly into the dorsomedial P

25 10mg/kg); in the striatum the treatment with MPH (10mg/kg) decreased caspase-3 and cytochrome c; trea

26 hrome c were reduced in the hippocampus with MPH (10mg/kg).

27 wks) at rest and with treadmill exercise (3 mph, 15 degrees incline, 10 mins).

28 the Bcl-2 and caspase-3 were increased with MPH (1mg/kg) and were reduced with MPH (2 and 10mg/kg);

29 d caspase-3 and cytochrome c; treatment with MPH (2 and 10mg/kg) increased Bax and decreased Bcl-2 in

30 n of Bcl-2, caspase-3, and cytochrome c with MPH (2 and 10mg/kg); in the striatum the treatment with

31 ased with MPH (1mg/kg) and were reduced with MPH (2 and 10mg/kg); the cytochrome c was reduced in the

32 n 2 d: after ingesting a single dose of oral MPH (20 mg) or placebo (lactose) in a counterbalanced fa

33 Targeting skeletal muscle myosin by MPH-220 enabled muscle relaxation, in human and model sy

34 MPH-220 provides a potential nervous-system-independent

35 tagenic analysis and the atomic structure of MPH-220-bound skeletal muscle myosin confirmed the mecha

36 allowed us to design a selective inhibitor, MPH-220.

37 g distance (12 blocks per week), and pace (2 mph), 26% of all new AF cases (95% CI 7% to 43%) appeare

38 For walking paces of less than 3.2 km/h (2.0 mph), 3.2 to 4.7 km/h (2.0-2.9 mph), and 4.8 km/h (3.0 m

39 osed 76 people to 10, 20, 30, 40, 50, and 60 mph (4.5, 8.9, 13.4, 17.9, 22.3, and 26.8 m/s) winds in

40 o the enzyme ([Fe(2+)]PAH(R)[L-Phe,5-deaza-6-MPH(4)]), the active site converts to a five-coordinate

41 nt in children, male rats were injected with MPH (5 mg/kg) or vehicle twice daily from postnatal day

42 eceived direct infusions of methylphenidate (MPH; 6.25, 25.0, or 100mug), amphetamine (AMPH; 0.25, 1.

43 ain any AIS > or = 2 injury was 37 kph [23.0 mph (95% CI, 32-45 kph)], and any AIS > or = 3 injury wa

44 and any AIS > or = 3 injury was 63 kph [39.1 mph (95% CI, 51-infinity kph)].

45 MRG was found in 22.7% of the isolates with mph(A) being the most commonly found gene.

46 The mph(A) gene plays the main role in the development of az

47 nt of azithromycin resistance and 93% of the mph(A)-carrying isolates showed a MIC of 32 mg/L.

48 Methylphenidate (MPH), a commonly used dopaminergic agent, may affect ani

49 ects of orally administered methylphenidate (MPH), a first-line treatment for attention deficit hyper

50 ts of two ADHD medications, methylphenidate (MPH), a psychostimulant, and atomoxetine (ATX), a select

51 ors contributed to the beneficial effects of MPH across both cognitive tasks.

52 The differential action of MPH across regions disappeared at higher concentrations.

53 associated with the procognitive actions of MPH across working memory and sustained attention tasks.

54 This work suggests that MPH, acting via noradrenergic mechanisms, can substantia

55 MPH administration improved behavioral performance and i

56 system and behavior, and also suggests that MPH administration may not have long-term consequences.

57 Finally, there were no effects of MPH administration on any reported measure.

58 Our findings indicate that MPH administration, beginning before puberty, and which

59 ng increased extracellular DA resulting from MPH administration.

60 mining the effects of 40 mg methylphenidate (MPH) administration.

61 MPH also improved reaction times to make correct respons

62 resonance imaging (fMRI) studies showed that MPH altered cortico-striatal resting functional connecti

63 Methylphenidate (MPH) ameliorates attention problems experienced by some

64 n Brain Development-Methylphenidate, or ePOD-MPH) among ADHD referral centers between October 13, 201

65 sive choice was not altered significantly by MPH, AMPH, or ATO into either mPFC or OFC, indicating th

66 An increase of wind speed above 4 mph (an increase of CO above 1.44 mg/m(3)) significantly

67 [(1)(1)C]MPH and [(1)(1)C]raclopride dynamic PET scans were perfo

68 ter (DAT) levels and enhances the potency of MPH and amphetamine on dopamine responses and drug-seeki

69 We found that MPH and ATX had similar effects on SICI.

70 In conclusion, MPH and ATX have similar effects on SICI in children wit

71 Both MPH and ATX increased SICI in heterozygotes but not in 1

72 ences the neurophysiological effects of both MPH and ATX.

73 le of the PFC in the procognitive actions of MPH and demonstrate the divergent dose sensitivity acros

74 erm neurobiological consequences of combined MPH and FLX treatment (MPH + FLX) during juvenile period

75 ERK2 activity within the VTA, we rescued the MPH and FLX-induced behavioral deficits seen in the forc

76 shed placebo controlled trials that compared MPH and placebo on executive and nonexecutive memory, re

77 ed decreased striatal D2R availability after MPH and these decreases were smaller in METH than in con

78 ally to reach a maximal speed of 9.7 km/h (6 mph) and a maximal inclination of 10degrees.

79 erage speed of 8.7 +/- 0.5 km/h (5.4 +/- 0.3 mph) and at an inclination of 3.3degrees +/- 2degrees.

80 se in the concurrent use of methylphenidate (MPH) and fluoxetine (FLX) in pediatric populations.

81 3.2 km/h (2.0 mph), 3.2 to 4.7 km/h (2.0-2.9 mph), and 4.8 km/h (3.0 mph) or more, compared with no r

82 ning (MAAT/MPH>MAAT/placebo and MAAT/MPH>ABT/MPH), and auditory working memory and divided attention

83 CA and dominance-related effects for SCA and MPH, and additive-by-dominant effect for MPH was partly

84 mph impacts, to 68% with chest impact at 40 mph, and then diminished at >/=50 mph (p < 0.0001).

85 psychostimulants, including methylphenidate (MPH), are highly effective in the treatment of attention

86 se in boys newly diagnosed with ADHD predict MPH-associated changes in ADHD inattentiveness and hyper

87 Our results showed that MPH at all doses increased Bax in the cortex; the Bcl-2

88 cerebellum there was an increase of Bax with MPH at all doses, however, there was a reduction of Bcl-

89 s reduced in the cortex after treatment with MPH at all doses; in the cerebellum there was an increas

90 o, we investigated if chronic treatment with MPH at doses of 1, 2 and 10mg/kg could alter the levels

91 neurobiological consequences of exposure to MPH at high, abused doses are not well defined.

92 s with a regulation baseball delivered at 30 mph at three sites over the cardiac silhouette (i.e., di

93 The effects of methylphenidate (MPH), atomoxetine (ATMX), and/or physical exercise (EX)

94 ation (with QRS strikes) were produced by 30-mph baseball impacts to the precordium.

95 in DAT1, previously linked to ADHD risk and MPH behavioural responses, influences the neurophysiolog

96 d DA/NE re-uptake inhibitor methylphenidate (MPH), both with proven clinical efficacy in ADHD, on the

97 mposed of patients who were not administered MPH (brain tumor = 31 and acute lymphoblastic leukemia =

98 Treatment with MPH can at least temporarily reduce some attentional and

99 gest that elevated catecholamine activity by MPH can disrupt inhibitory influences on persistent risk

100 e rehabilitation (MAAT) and pharmacotherapy (MPH) can improve aspects of attention, episodic and work

101 an in controls, and had no D2R changes after MPH challenge.

102 We measured the impact of MPH, compared with placebo, on behavioral and electrocor

103 mine transporter (DAT1), a site of action of MPH, could influence the effects of MPH or ATX on SICI.

104 It was not possible to resolve whether MPH delayed the initiation of the onset of puberty or re

105 lysis of human monocyte-derived macrophages (Mph) demonstrated greater susceptibility to human influe

106 Chronic MPH did not differentially alter the course of weight ga

107 with therapeutic doses of sustained release MPH did not have a significant influence on the regulati

108 be pathologies; however, in clinical trials, MPH did not improve treatment outcome in cocaine addicti

109 Impacts at 20 mph did not induce VF; incidence of VF increased increme

110 th Nile Red-positive adipocytes, we found MC/Mph distributed in cell cords, also containing various m

111 connectivity (FC) associated with the first MPH dose in boys newly diagnosed with ADHD predict MPH-a

112 ndisplaceable binding potential (BP(ND)) and MPH dose in the head of the caudate (hCd), demonstrating

113 inutes after the administration of the first MPH dose to 40 stimulant drug-naive boys newly diagnosed

114 s will be required to establish that the MC-/Mph-drilled tunnels evolve to become capillaries, connec

115 George W. Comstock (1915-2007), MD, MPH, DrPH, was lecturer and then professor of epidemiolo

116 Here we show in rats that exposure to MPH during pre-adolescence causes behavioral and neurobi

117 No trend was observed for MPH effectiveness in improving learning of a word associ

118 ological markers in 16 regions implicated in MPH effects and/or ADHD etiology.

119 ese findings are discussed in the context of MPH effects on the default mode network and the possible

120 A dose of 1 mg/kg intraperitoneal MPH, either single dose or chronic treatment (well withi

121 Low concentrations of MPH elicited significantly larger increases in extracell

122 MPH enhanced activity within individual neurons, ensembl

123 MPH enhances catecholamine transmission via blockade of

124 it is well established that methylphenidate (MPH) enhances sustained attention, the neural mechanisms

125 At PND135, MPH-exposed rats exhibited decreased anxiety in the elev

126 alamus neuropeptide Y-ir increased by 10% in MPH-exposed rats.

127 ats showed major structural differences with MPH exposure.

128 MPH + FLX enhanced sensitivity to drug (i.e., cocaine) a

129 MPH + FLX exposure also increased mRNA of ERK2 and its d

130 These results indicate that concurrent MPH + FLX exposure during preadolescence increases sensi

131 VTA) to determine the effect of MPH, FLX, or MPH + FLX on the extracellular signal-regulated protein

132 We administered saline (VEH), MPH, FLX, or MPH + FLX to juvenile Sprague Dawley male rats from post

133 sequences of combined MPH and FLX treatment (MPH + FLX) during juvenile periods are unknown.

134 mental area (VTA) to determine the effect of MPH, FLX, or MPH + FLX on the extracellular signal-regul

135 We administered saline (VEH), MPH, FLX, or MPH + FLX to juvenile Sprague Dawley male r

136 of these complex signals on infiltrating Mo/Mph following UV exposure, we then tested the effects of

137 treated with either 0, 2, 4, or 8 mg/kg/day MPH for 3 weeks.

138 ained sedentary or ran on a treadmill at 0.6 mph for 30 min (n = 9-12 per group) and received a bolus

139 Attention and behavioral benefits of MPH for childhood cancer survivors are maintained across

140 Funding assistance for AD's MPH from Scottish Intensive Care Society, Scottish Socie

141 In contrast, subjects treated with MPH gambled at a consistent rate, well above chance, acr

142 IT (24.0 min vs. 24.0 min, p = .89), but the MPH group demonstrated shorter median operative WIT (cir

143 ebo group, the 15 patients randomized to the MPH group had a significantly greater improvement on the

144 A trend for greater improvement in the MPH group on a measure of verbal memory failed to reach

145 ; age range, 10-12 years) and 48 men (n = 24 MPH group, n = 24 placebo group; age range, 23-40 years)

146 e error correction.ResultsFifty boys (n = 25 MPH group, n = 25 placebo group; age range, 10-12 years)

147 For the MPH group, repeated measures analysis of variance reveal

148 bal learning (MAAT/MPH>MAAT/placebo and MAAT/MPH>ABT/MPH), and auditory working memory and divided at

149 y working memory and divided attention (MAAT/MPH>ABT/MPH).

150 acebo>ABT/placebo), nonverbal learning (MAAT/MPH>MAAT/placebo and MAAT/MPH>ABT/MPH), and auditory wor

151 h, those that habitually walked at a pace >3 mph had a lower risk of coronary heart disease (0.50; co

152 mental exposure to high therapeutic doses of MPH has short-term effects on select neurotransmitters i

153 Methylphenidate (MPH) has long been used to treat attention-deficit/hyper

154 Wind storms with wind speeds of up to 70 mph have not been effective in removing significant amou

155 timulant medication such as methylphenidate (MPH); however, approximately 25% of patients show little

156 f VF increased incrementally from 7% with 25 mph impacts, to 68% with chest impact at 40 mph, and the

157 Psychostimulants, including methylphenidate (MPH), improve cognitive processes dependent on the prefr

158 In both humans and animals, systemic MPH improves certain cognitive processes, such as workin

159 is that the psychostimulant methylphenidate (MPH) improves cognitive and social functioning among the

160 , we tested for modulation of this effect by MPH in 40 healthy human adults.

161 Here, we characterized the behavior of MC/Mph in cellular infiltrates, with emphasis on their spat

162 Here we investigated the effects of MPH in thalamic connectivity since the thalamus modulate

163 ed premature responding whereas infusions of MPH in the core, but not the shell, sub-region significa

164 The opposing effects of ATO and MPH in the NAcb core and shell on impulsivity were unlik

165 ation of stimulants such as methylphenidate (MPH) in children with attention deficit hyperactivity di

166 ation of fluorescently labeled peritoneal MC/Mph incorporated in Matrigel-containing fluorescent prot

167 During transient inhibition, MPH increased prefrontal activation for both groups and

168 Results show that oral MPH increased responses to this salient cognitive task i

169 kg (low dose, n = 10), or (iii) 1.5 mg/kg of MPH increased to 12.5 mg/kg (high dose, n = 10) for a to

170 L/kg of vehicle (n = 10), (ii) 0.15 mg/kg of MPH increased to 2.5 mg/kg (low dose, n = 10), or (iii)

171 t increase in the parietal P3 amplitude with MPH, indicative of enhanced perceptual evidence accumula

172 The clinical application of such MPH-induced brain-behavior enhancements remains to be te

173 These results, showing that MPH-induced changes in DA levels in the hCd predict rest

174 Our main analysis showed a significant MPH-induced FC increase in sensorimotor areas in the fun

175 In these studies, MPH-induced improvement in sustained attention was aboli

176 e alpha(1)-antagonist prazosin (.5 mg/kg) on MPH-induced improvement in sustained attention was exami

177 owever, alpha1 receptors only contributed to MPH-induced improvement in sustained attention.

178 lower for the placebo and MPH measures, that MPH-induced increases in thalamic metabolism were blunte

179 In our exploratory analysis, we found that MPH-induced regional variations in the DAT and NET-enric

180 neither in striatal D2R availability nor in MPH-induced striatal DA changes.

181 llin-1 is required for AMPH-induced, but not MPH-induced, hyperlocomotion.

182 We examined how MPH influenced known electrophysiological precursors of

183 In conclusion, our results suggest that MPH influences plasticity in the brain of young and adul

184 ent on multiple frontostriatal regions, only MPH infusion into the dorsomedial PFC improved task perf

185 ssary for accurate performance in this task, MPH infusion into this region did not affect working mem

186 a novel mechanism for induction of tissue Mo/Mph into an IL-10high/IL-12low state via iC3b in combina

187 MPH is also used, without license, by healthy adults, bu

188 Methylphenidate (MPH) is a first line treatment for ADHD and is also misu

189 Methylphenidate (MPH) is a stimulant that increases extracellular levels

190 Methylphenidate (MPH) is an effective symptomatic treatment of attention

191 Methylphenidate (MPH) is an effective treatment for ADHD symptoms, but it

192 Methylphenidate (MPH) is commonly diverted for recreational use, but the

193 Methylphenidate (MPH) is commonly prescribed for children who have been d

194 BackgroundMethylphenidate (MPH) is highly effective in treating attention-deficit/h

195 Methylphenidate (MPH) is used clinically to treat attention-deficit/hyper

196 scopicity of PM emissions at high speeds (70 mph; kappa > 1) are much larger than emissions at low sp

197 much larger than emissions at low speeds (30 mph; kappa < 0.1).

198 MPH led to an overall suppression of alpha activity acro

199 MPH led to increased rates of target detection, and elec

200 r destruction of the matrix (tunnels) and MC/Mph-lined capillary-like structures occasionally contain

201 ime, chronic modulation of young brains with MPH may exert effects on brain neurochemistry that modif

202 Although academic gains were not identified, MPH may offer benefits in academic areas not assessed.

203 Juvenile treatment with MPH may result in long-lasting, potentially permanent, c

204 <0.001; cumulative PH: MD -0.287, P <0.001; MPH: MD -0.288, P <0.001; DPH: MD -0.310, P <0.001).

205 0.010; DPH: MD -0.765, P <0.001; mesial PH [MPH]: MD -0.285, P = 0.256).

206 leus accumbens was lower for the placebo and MPH measures, that MPH-induced increases in thalamic met

207 on was correlated with the initial 90-minute MPH-mediated FC changes.

208 at 3 months were associated with first-dose MPH-mediated FC reductions restricted to frontal-prefron

209 core improvement was associated with initial MPH-mediated FC reductions restricted to occipitoparieta

210 possible role of the default mode network in MPH-mediated improvements in inattention and hyperactivi

211 eractivity scores over the first 3 months of MPH medication was correlated with the initial 90-minute

212 To this end, we studied MC/Mph migration and assembly in basic fibroblast growth fa

213 hite matter (WM).PurposeTo determine whether MPH modulates WM microstructure in an age-dependent fash

214 , yielding four treatment combinations: MAAT/MPH (N=17), ABT/MPH (N=19), MAAT/placebo (N=17), and ABT

215 treatment combinations: MAAT/MPH (N=17), ABT/MPH (N=19), MAAT/placebo (N=17), and ABT/placebo (N=18).

216 In contrast to the SHRs, neither MPH nor ATMX affected orienting or social behavior in Wi

217 Methylphenidate (MPH) normalizes cortical function, enhancing task salien

218 ere measured during moderate exercise at 2.8 mph on a treadmill.

219 found no relationship between the effects of MPH on impulsivity and D2/3 receptor availability in any

220 vation period, suggesting that the impact of MPH on puberty is not permanent.

221 erved opposing actions of low- and high-dose MPH on the population-based representation of delay: low

222 support the potentially important effects of MPH on various aspects of cognition known to be associat

223 ant to note that EX was just as effective as MPH or ATMX in reducing orienting behavior and social in

224 ction of MPH, could influence the effects of MPH or ATX on SICI.

225 riatum, which is normalized following either MPH or l-dopa administration.

226 th either a sustained release formulation of MPH or placebo (N=8 per group).

227 nitive complaints were randomized to receive MPH or placebo and MAAT or ABT, yielding four treatment

228 ia were randomized to undergo treatment with MPH or placebo for 16 weeks.

229 (PD90) Sprague Dawley rats were treated with MPH or saline.

230 to 4.7 km/h (2.0-2.9 mph), and 4.8 km/h (3.0 mph) or more, compared with no regular walking, RRs were

231 gical enhancement (ie, with methylphenidate (MPH) or placebo), for treating persistent cognitive prob

232 and [(18)F]fallypride, rats received 6 mg/kg MPH, orally, twice each day for 28 d.

233 pact at 40 mph, and then diminished at >/=50 mph (p < 0.0001).

234 s and organogenesis and in which cells of MC/Mph phenotype play a key structural role.

235 MPH produced a broad inverted-U-shaped facilitation of s

236 Many of these MC/Mph produced MMP-12- and TIMP-1-dependent tunnels couple

237 all crashes was 29 +/- 16.9 kph [18 +/- 10.5 mph (range, 5-123 kph)].

238 When the subjects were not taking MPH, rCBF was higher in the motor, premotor, and the ant

239 In hippocampal dentate gyrus, MPH-receiving rats showed a 51% decrease in NET-ir densi

240 lamus and accumbens in CUD was normalized by MPH (reducing negative connectivity).

241 MPH-related enhancements occurred without significant ch

242 Our findings show that main MPH-related FC changes at rest can be understood through

243 MPH resulted in a statistically significant improvement

244 xamined the degree to which methylphenidate (MPH) (Ritalin) acts within distinct frontostriatal subfi

245 n rodents demonstrates that methylphenidate (MPH; Ritalin) elicits a narrow inverted-U-shaped improve

246 ousands of children receive methylphenidate (MPH; Ritalin) for attention deficit/hyperactivity disord

247 MPH's normalization of thalamo-accumbens connectivity (r

248 Pharmacotherapy with methylphenidate (MPH) seems to be the first-line treatment of choice in a

249 Here we show that MPH self-administration in rats increases dopamine trans

250 n mice mimics these effects, confirming that MPH self-administration-induced increases in DAT levels

251 MPH serves to reduce maladaptive electrophysiological pr

252 edial prefrontal cortex (mPFC) of rats given MPH showed 55% greater immunoreactivity (-ir) for the ca

253 However, neither ATO nor MPH significantly altered impulsive behavior when infuse

254 MPH significantly increased thalamo-cerebellar connectiv

255 reversed by treatment with methylphenidate (MPH), suggesting a defect in brain catecholamine homeost

256 rom trait phenotype, and fewer QTL were from MPH than from other dependent variables.

257 xample, in comparison with a walking pace <2 mph, those that habitually walked at a pace >3 mph had a

258 nvestigated the transgenerational effects of MPH through the paternal line.

259 The potential of monocytes/macrophages (MC/Mph) to contribute to neovascularization has recently be

260 treated with methylphenidate hydrochloride (MPH) to evaluate genetic and behavioral toxicity were ob

261 r challenge with 60 mg oral methylphenidate (MPH) (to measure DA release) to assess whether it predic

262 washout, the D2/D3 receptor availability of MPH-treated animals did not continue to decline at the s

263 se in FA (standardized effect size, 5.25) in MPH-treated boys.

264 the long-term neurochemical consequences of MPH treatment are unknown.

265 interaction between environment and chronic MPH treatment at clinically relevant doses, administered

266 MPH treatment increased impulsivity in LI rats, and modu

267 Brief discontinuation of MPH treatment is associated with increased motor and ant

268 Our findings suggest that MPH treatment modulates motor and anterior cingulate cor

269 ed the effects of discontinuation of chronic MPH treatment on regional cerebral blood flow (rCBF) in

270 Recovery from MPH treatment was also examined at 1, 5, and 10 weeks fo

271 Before MPH treatment, we found that D2/3 receptor availability

272 he commonly occurring brief interruptions in MPH treatment.

273 ined the effects of chronic methylphenidate (MPH) treatment on brain dopamine (DA) systems, developme

274 Eligibility criteria for the MPH trial included an estimated intelligence quotient gr

275 premedication baseline and at the end of the MPH trial while on medication.

276 on (<15 min), low-velocity ( approximately 1 mph) walking bouts.

277 Here, MPH was evaluated for its potential to alter stimulus-dr

278 ons in the core and shell, or increased when MPH was infused into either the core and shell sub-regio

279 and MPH, and additive-by-dominant effect for MPH was partly identified as additive effect; 2) the ran

280 red to placebo, significant improvement with MPH was reported by teachers and parents on the Conners'

281 ute exercise (5 minutes at 3.6, 5.9, and 9.1 mph) was performed, and hemodynamic measurements and blo

282 endurance exercise (up to 90 minutes at 4.5 mph) was performed.

283 ated the murine poliovirus receptor homolog (Mph), was found to be a receptor for the porcine alphahe

284 The effects of varying doses of MPH were examined on performance of rats in two tests of

285 Impacts at 40 mph were more likely to produce VF than impacts with gre

286 No significant side effects from MPH were observed.

287 therapeutic drugs, such as methylphenidate (MPH), which also alters behavioral and cognitive functio

288 Here, we focus on methylphenidate (MPH), which binds to the dopamine transporter (DAT) and

289 We also show that methylphenidate (MPH), which competitively inhibits DA uptake but does no

290 CD11b+ monocytic/macrophagic cells (Mo/Mph), which infiltrate into skin after UV irradiation, p

291 indings identify the thalamus as a target of MPH, which increased its metabolism and connectivity.

292 nd experiment, 20 subjects received 20 mg of MPH, while 20 matched controls received a placebo.

293 We hypothesized that oral MPH will attenuate ACC hypoactivations and improve assoc

294 le-dose, crossover study comparing 0.5 mg/kg MPH with 1.0 mg/kg ATX in 16 children with ADHD, aged 8-

295 s found for the SLC6A3 40 bp and response to MPH with only two studies selected.

296 lternatively, our findings may be related to MPH withdrawal.

297 We hypothesized that MPH would increase thalamic connectivity and metabolism,

298 xploratory decisions than controls, and that MPH would reduce group differences.

299 001) and (CTB: 43 +/- 6.7 vs SCT 1.4 +/- 1.0 mpH x min(-1) x 100 ng DNA(-1), p < 0.0001).

300 0.07 to 0.20); proportion of schools with 20 mph zones (RR 1.47, 95%CI: 0.93 to 2.32), Safe Routes to